Please login to the form below
Novavax
This page shows the latest Novavax news and features for those working in and with pharma, biotech and healthcare.
US trial data shows Novavax’s COVID-19 vaccine is 90% effective
In a statement, Novavax said sequence data was available for 54 of the 77 COVID-19 cases observed in the trial. ... By the end of the fourth quarter of 2021, Novavax said it is also on track to manufacture 150 million doses per month.
Latest news
-
Novavax announces further delays for regulatory filings of COVID-19 vaccine
Novavax is also expecting data from a US-based phase 3 trial of its COVID-19 vaccine, involving 30, 000 volunteers, in “a few weeks”, according to Erck. ... Based on this information, Novavax calculated that its vaccine is 95.6% effective against the
-
Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
Earlier this year, reports emerged that Novavax has encountered issues with sourcing some raw materials used in the manufacturing process for NVX-CoV2373. ... The UK government has already signed an advanced purchase agreement with Novavax for 60 million
-
Moderna agrees to supply Gavi with 500 million doses for COVAX
A number of other major vaccine developers have previously signed supply agreements with COVAX, including Sanofi and GlaxoSmithKline, Pfizer/BioNTech and AstraZeneca, while Novavax recently announced a memorandum of understanding with
-
GSK’s revenue drops by 18% in Q1 as performance pressures mount
agreement to help make Novavax’s vaccine candidate.
-
Oxford University’s malaria vaccine is 77% effective
Two groups were allocated to received the R21/Matrix-M vaccine – either with a low dose or high dose of Novavax’s Matrix-M adjuvant – while the third control group received
More from news
Approximately 17 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Developing a COVID-19 vaccine
The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
-
Deal Watch table for June 2013
30. Isconova / Novavax. Acquisition. Proprietary vaccine adjuvant technology. 30. Unless noted, transactions are for global rights.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck enters agreement with Hanmi for investigational NASH drug
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Novo Nordisk growth takes a hit with China deal
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
